Cargando…
Androgen Receptor Variant–Driven Prostate Cancer II: Advances in Laboratory Investigations
BACKGROUND: The androgen receptor (AR) is a key prostate cancer drug target. Suppression of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing AR-directed therapies. AR-targeting agents impart therapeutic benefit, but lead to AR aberrations that underlie dise...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725416/ https://www.ncbi.nlm.nih.gov/pubmed/32139878 http://dx.doi.org/10.1038/s41391-020-0217-3 |